Hazardous Medication List

Similar documents
Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

MEDICAL NECESSITY GUIDELINE

PHARMACY PEARLS CHANIN WRIGHT, PHARMD

Objectives 5/19/2017. Hazardous Drugs Sunnybrook Health Sciences Centre s Experience. Hazardous Drug Committee at Sunnybrook

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Supplementary Figures

Exposure Control Plan for Cytotoxic Substances


SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25

See Important Reminder at the end of this policy for important regulatory and legal information.

Subject: Palonosetron Hydrochloride (Aloxi )

See Important Reminder at the end of this policy for important regulatory and legal information.

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Part B payment for drugs in Medicare 0

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Chemotherapy 101 for Radiation Oncology Workers

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Part B payment for drugs in Medicare 0

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

Guidelines for the Use of Anti-Emetics with Chemotherapy

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Acute Lymphocytic Leukemia

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

Emetogenicity level 1. Emetogenicity level 2

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Systemic Anticancer Therapy Drug Interactions Table

Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care

DRUG PROPERTIES YOU NEED TO KNOW

The AngCN Antiemetic Guidelines

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

MASCC Guidelines for Antiemetic control: An update

Managements of Chemotherpay Induded Nausea and Vomiting

DRUG PROPERTIES YOU NEED TO KNOW

Working Formulary January 2013 Oncology Chemotherapy Regimens

Cancer drug approvals for paediatric indications (n=43)

Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy

ANTIEMETIC GUIDELINES: MASCC/ESMO

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)

COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH

DRUGS YOU NEED TO KNOW

Haematology, Oncology and Palliative Care Directorate.

1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Chemotherapeutics. Andrew Stolbach

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

8. Malignant disease and immunosuppression

Chemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

8. Malignant disease and immunosuppression

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Guideline Update on Antiemetics

Clinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS

8. Malignant disease and immunosuppression

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

National Cancer Drugs Fund List - Approved

Clinical Tools and Resources for Self-Study and Patient Education

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Domperidone: Drug Interactions & Cautions (Mayo Clinic)

NICE TA Adherence Check List

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

Update on antiemetics, what is new and future directions. Karin Jordan University of Halle

Prior Authorization Proposal: Oncology Agents

REVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Northern Cancer Alliance

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015

Transcription:

Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF

Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling Considerations for Specified Hazardous Medication... 5 Precautionary Period for KNOWN Hazard Medication... 6 i

Hazardous Medication List Key Points Indicates the medication is a CYTOTOXIC agent. The following products are NOT listed on the Hazardous Medication List, but may require special handling precautions: Salts, PEGylated and liposomal medication - only the parent compound is listed (e.g. doxorubicin) Combination products containing a hazardous medication (e.g. spironolactone-hydrochlorothiazide) Investigational / Clinical Trial medication as toxicological data is often incomplete or unavailable Chemicals and / or raw powders; follow the Safety Data Sheet (SDS) for safe handling precautions Radiopharmaceuticals; Nuclear Medicine has policies and procedures for the handling of these products The Hazardous Medication List will be reviewed and updated on a periodic basis as new medication or information becomes available. Refer to Insite for the most current version. 1

A Hazardous Medication List abacavir alitretinoin apomorphine abatacept altretamine arsenic trioxide abiraterone ambrisentan axitinib acitretin amsacrine azacitidine afatinib anagrelide azathioprine alefacept anastrozole B BCG bicalutamide bosutinib belinostat bleomycin brentuximab vedotin bendamustine bortezomib buserelin bexarotene bosentan busulfan C cabazitaxel chlorambucil clonazepam cabergoline chloramphenicol colchicine cabozantinib choriogonadotropin crizotinib capecitabine alpha cyclophosphamide carbamazepine cidofovir cyclosporine CARBOplatin CISplatin cyproterone carfilzomib cladribine cytarabine carmustine clofarabine cetrorelix acetate clomiphene D dabrafenib deferiprone DOXOrubicin dacarbazine degarelix dronedarone dactinomycin dexrazoxane dutasteride danazol diethylstilbesterol dasatinib dinoprostone DAUNOrubicin divalproex sodium decitabine DOCEtaxel E entecavir erlotinib estrogen / enzalutamide eslicarbazepine progesterone combinations epirubicin estradiol ergonovine estramustine estropipate (ergometrine) / estrogen - esterfied etoposide methylergonovine everolimus estrogen - conjugated eribulin exemestane 2

Hazardous Medication List F finasteride fludarabine fosphenytoin fingolimod fluorouracil (5FU) fulvestrant floxuridine fluoxymesterone fluconazole flutamide G ganciclovir gemcitabine gonadotropin, ganirelix acetate chorionic gemtuzumab gefitinib ozogamicin goserelin H histrelin hydroxyurea I ibrutinib ifosfamide ISOtretinoin icatibant imatinib ixabepilone IDArubicin irinotecan ixazomib J / K L lapatinib leuprolide lomitapide leflunomide lenalidomide letrozole M liraglutide recombinant lomustine macitentan methimazole mitomycin medroxyproges methotrexate mitotane -TERone methyltestos- mitoxantrone megestrol TERone mycophenolate melphalan mifepristone mofetil menotropins mipomersen mycophenolic acid mercaptopurine misoprostol N nafarelin nevirapine nilutamide nelarabine nilotinib O omacetaxin oxaliplatin OXcarbazepine ospemifene oxandrolone oxytocin 3

Hazardous Medication List P PACLitaxel pemetrexed plerixafor PACLitaxel-(nab) pentamidine pomalidomide palifermin pentetate calcium ponatinib paliperidone pentostatin porfimer pamidronate pertuzumab pralatrexate panobinostat phenoxybenzamine procarbazine PARoxetine phenytoin progesterone pasireotide piritrexim isethionate pazopanib propylthiouracil peginesatide pipobroman Q R progestins raloxifene regorafenib risperidone raltitrexed ribavirin romidepsin rasagiline riociguat ruxolitinib S sirolimus spironolactone SUNItinib SORAfenib streptozocin T tacrolimus testosterone trametinib tamoxifen thalidomide telavancin thioguanine trastuzumab emtansine (Kadcyla) temazepam thiotepa tretinoin temozolomide tofacitinib temsirolimus topiramate trifluridine / tipiracil (combination only) teniposide topotecan triptorelin U ulipristal uracil mustard V valganciclovir vemurafenib vinorelbine valproate / valproic acid vigabatrin vismodegib vinblastine voriconazole valrubicin vincristine vorinostat vandetanib W X Y warfarin Z zidovudine ziv-aflibercept zonisamide ziprasidone zoledronic acid 4

Special Handling Considerations for Specified Hazardous Medication BCG vaccine (bacillus calmette Guerin) BCG, although classified as a vaccine, is used in the treatment of certain cancers. BCG should be prepared with aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves, and a gown should be worn to avoid inhalation or contact with BCG organisms. Follow special handling guidelines. Pentamidine For inhalation (administered by respiratory therapist). Follow special handling guidelines. Monoclonal Antibodies (mabs) While many monoclonal antibodies are classified by American Hospital Formulary Service (AHFS) as 10:00 antineoplastic medication, they are not typically classified as hazardous medication by NIOSH. These medications should be handled using aseptic technique. Monoclonal antibodies included on the Hazardous Medication List require handling precautions as per the PPE Guide. 5

Precautionary Period for KNOWN Hazard Medication Precautionary Period for KNOWN Hazard Medication Requiring PPE for Longer than 48 hours* Hazardous Medication Detected in Urine Detected in Stool or Bile carmustine At least 4 days -- CISplatin At least 5 days -- DOCEtaxel 6% excretion Up to 7 days DOXOrubicin 5% excretion for up to 5 days Up to 7 days etoposide At least 5 days -- gemcitabine At least 7 days -- imatinib mesylate 13% excretion for up to 7 days Up to 7 days methotrexate (oral) Up to 5 days Up to 5 days mitoxantrone Up to 5 days Up to 5 days temsirolimus 4.6% excretion for up to 14 days teniposide Up to 5 days -- 78% excretion for up to 14 days vincristine Minimal excretion Up to 3 days vinorelbine Minimal excretion At least 3 days *All KNOWN hazard medication on the AHS Hazardous Medication List require 48 hours handling precautions except those listed above. For further questions contact AHS Drug Information. Note: Based on information from the American Society of Health-System Pharmacists, 2009, Thomson Reuters Micromedex 2.0, 2009. Source: Oncology Nursing Society Safe Handling of Hazardous Drugs, 2 nd Edition, 2011, p. 48. 6

Developed by: AHS Hazardous Medication Evaluation Committee (HazMEC) and the AHS Hazardous Medication Evaluation Panel, AHS Pharmacy Services Medication Quality and Safety Team (MQST), AHS Health Professions, Strategy and Practice (HPSP), AHS Pharmacy Services Technical Practice Leads, AHS Human Factors, AHS Workplace Health and Safety (WHS), and COV Medication Management & Safety Team. Acknowledgements to: AHS Cancer Control, Eastern Health - Newfoundland, British Columbia Cancer Agency (BCCA), and Winnipeg Regional Health Authority (WRHA) for their work on hazardous medications. If you have questions, please contact a WHS Advisor in your zone. Document History Document Version Revision Date Original Document (V1.0) Dec 2017 Revision #1 Next Revision Due 7

8